Page 139 - 《中国药房》2026年10期

（9）：919-926. poietic stem cell transplant[J]. Transpl Infect Dis，2019，21
[37] LAZZARO C. Economic evaluation of posaconazole in （5）：e13148.
prophylaxis of invasive fungal infections in Italian neutro‐ [47] STAM W B，O’SULLIVAN A K，RIJNDERS B，et al.
penic patients with acute myeloid leukaemia or myelodys‐ Economic evaluation of posaconazole vs. standard azole
plastic syndrome[J]. Infez Med，2010；18（2）：91-103. prophylaxis in high risk neutropenic patients in the Nether‐
[38] JUNJARUNEE S，NUMUANG K，LERDLITRUANGSIN lands[J]. European J Haematology，2008，81（6）：467-474.
S，et al. Cost-effectiveness of posaconazole versus flucona- [48] DRANITSARIS G，KHOURY H. Posaconazole versus flu‐
zole or itraconazole in the prophylaxis of invasive fungal conazole or itraconazole for prevention of invasive fungal
infections among neutropenic patients in Thailand[J]. infections in patients undergoing intensive cytotoxic
Value Health，2014，17（7）：A806. therapy for acute myeloid leukemia or myelodysplasia：a
[39] LUNDBERG J，HÖGLUND M，BJÖRKHOLM M，et al. cost-effectiveness analysis[J]. Support Care Cancer，2011，
Economic evaluation of posaconazole versus fluconazole 19（11）：1807-1813.
or itraconazole in the prevention of invasive fungal infec‐ [49] HENG S C，SLAVIN M A，AL-BADRIYEH D，et al.
tion in high-risk neutropenic patients in Sweden[J]. Clin Pharmacoeconomic evaluation of fluconazole，posacona-
Drug Investig，2014，34（7）：483-489. zole and voriconazole for antifungal prophylaxis in pa‐
[40] O’SULLIVAN A K，PANDYA A，PAPADOPOULOS G， tients with acute myeloid leukaemia undergoing first con‐
et al. Cost-effectiveness of posaconazole versus flucona- solidation chemotherapy[J]. J Antimicrob Chemother，
zole or itraconazole in the prevention of invasive fungal 2013，68（7）：1669-1678.
infections among neutropenic patients in the United States [50] MICHALLET M，GANGNEUX J P，LAFUMA A，et al.
[J]. Value Health，2009，12（5）：666-673. Cost effectiveness of posaconazole in the prophylaxis of
[41] O’SULLIVAN A K，WEINSTEIN M C，PANDYA A，et invasive fungal infections in acute leukaemia patients for
al. Cost-effectiveness of posaconazole versus fluconazole the French healthcare system[J]. J Med Econ，2011，14
for prevention of invasive fungal infections in U. S. pa‐ （1）：28-35.
tients with graft-versus-host disease[J]. Am J Health Syst [51] ATHANASAKIS K，PETRAKIS I，KYRIOPOULOS J.
Pharm，2012，69（2）：149-156. Posaconazole vs fluconazole/itraconazole in the prophy‐
[42] TAHAMI MONFARED A A，O’SULLIVAN A K， laxis of invasive fungal infections in immunocompro‐
ROTSTEIN C，et al. Economic evaluation of posacona- mised patients：a cost-effectiveness analysis in Greece[J].
zole versus standard azole therapy as prophylaxis against J Med Econ，2013，16（5）：678-684.
invasive fungal infections in patients with prolonged neu‐ [52] SÁNCHEZ-ORTEGA I，PATIÑO B，MUÑOZ C，et al.
tropenia in Canada[J]. Can J Infect Dis Med Microbiol， Cost-effectiveness of primary antifungal prophylaxis with
2012，23（2）：59-64. posaconazole versus itraconazole in allogeneic hemato-
[43] TUON F F B，LINO FLORENCIO K，DA CUNHA C A， poietic stem cell transplantation[J]. J Med Econ，2013，16
et al. Cost-effectiveness of posaconazole in private and （6）：736-743.
public Brazilian hospitals[J]. Rev Iberoam De Micología， [53] CHAN T S Y，MARCELLA S W，GILL H，et al. Posacona-
2018，35（2）：63-67. zole vs fluconazole or itraconazole for prevention of in-
[44] UMIT E. Economic analysis of oral posaconazole prophy‐ vasive fungal diseases in patients with acute myeloid leu‐
laxis in acute myeloid leukemia during remission induc‐ kemia or myelodysplastic syndrome：a cost-effectiveness
tion in Turkey[J]. North Clin Istanbul，2019，7（3）： analysis in an Asian teaching hospital[J]. J Med Econ，
222-225. 2016，19（1）：77-83.
[45] PUNGPRASERT T， DHIRACHAIKULPANICH D， [54] 王彪，房文通，傅源源. 泊沙康唑预防血液恶性肿瘤患者
PHUTTHASAKDA W，et al. The cost-utility analysis of 侵袭性真菌感染的快速卫生技术评估[J]. 药物流行病学
antifungal prophylaxis for invasive fungal infections in 杂志，2021，30（10）：661-669.
acute myeloid leukaemia patients receiving chemo‐ [55] 柴双，展敬伦，肇丽梅，等 . 5 种三唑类抗真菌药物的药
therapy：a study from a middle-income country[J]. J Hosp 物不良反应分析[J]. 中国临床药理学杂志，2022，38
Infect，2024，145：118-128. （17）：2079-2083.
[46] WALKER B S，SCHMIDT R L，TANTRAVAHI S，et al. （收稿日期：2025-12-25 修回日期：2026-05-07）
Cost-effectiveness of antifungal prophylaxis，preemptive （编辑：陈 宏）
therapy，or empiric treatment following allogeneic hemato‐

中国药房 2026年第37卷第10期 China Pharmacy 2026 Vol. 37 No. 10 · 1369 ·